loading
Outlook Therapeutics Inc stock is traded at $2.68, with a volume of 3.68M. It is up +11.20% in the last 24 hours and up +28.85% over the past month. Outlook Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing and commercializing ONS-5010, a monoclonal antibody, or mAb, for various ophthalmic indications. The Company have received marketing authorization for an ophthalmic formulation of ONS-5010/LYTENAVA (bevacizumab-gamma) for use in treating wet age-related macular degeneration, or wet AMD, in the European Union, and United Kingdom. The product pipeline includes ONS-5010/LYTENAVA which is in total eight NORSES; ONS-5010 Clinical Progress, Unmet Patient Needs, New Ophthalmic Anti-VEGF, and Potential First Line Therapy.
See More
Previous Close:
$2.41
Open:
$2.46
24h Volume:
3.68M
Relative Volume:
3.50
Market Cap:
$89.96M
Revenue:
-
Net Income/Loss:
$-51.50M
P/E Ratio:
-0.67
EPS:
-4
Net Cash Flow:
$-47.10M
1W Performance:
+14.53%
1M Performance:
+28.85%
6M Performance:
+71.79%
1Y Performance:
-62.62%
1-Day Range:
Value
$2.38
$2.70
1-Week Range:
Value
$2.11
$3.0189
52-Week Range:
Value
$0.87
$8.32

Outlook Therapeutics Inc Stock (OTLK) Company Profile

Name
Name
Outlook Therapeutics Inc
Name
Phone
(609) 619-3990
Name
Address
111 S. WOOD AVENUE, ISELIN, NJ
Name
Employee
23
Name
Twitter
Name
Next Earnings Date
2024-08-14
Name
Latest SEC Filings
Name
OTLK's Discussions on Twitter

Compare OTLK with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Biotechnology icon
OTLK
Outlook Therapeutics Inc
2.68 118.70M 0 -51.50M -47.10M -4.00
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
395.12 99.96B 11.39B 3.64B 3.50B 13.99
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
589.48 60.83B 14.21B 4.46B 3.56B 39.68
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
454.38 59.89B 2.46B -319.09M -52.09M -2.47
Biotechnology icon
ARGX
Argen X Se Adr
660.00 40.47B 3.06B 1.28B 447.35M 21.30
Biotechnology icon
ONC
Beone Medicines Ltd Adr
313.67 37.96B 3.81B -644.79M -669.77M -6.24

Outlook Therapeutics Inc Stock (OTLK) Upgrades & Downgrades

Date Action Analyst Rating Change
Dec-02-24 Downgrade Chardan Capital Markets Buy → Neutral
Mar-27-24 Upgrade BTIG Research Neutral → Buy
Feb-15-24 Upgrade Chardan Capital Markets Neutral → Buy
Jan-25-24 Upgrade Guggenheim Neutral → Buy
Dec-27-23 Upgrade CapitalOne Equal Weight → Overweight
Aug-31-23 Downgrade Chardan Capital Markets Buy → Neutral
Aug-31-23 Downgrade H.C. Wainwright Buy → Neutral
Aug-30-23 Downgrade BTIG Research Buy → Neutral
Aug-30-23 Downgrade Cantor Fitzgerald Overweight → Neutral
Aug-30-23 Downgrade CapitalOne Overweight → Equal Weight
Aug-30-23 Downgrade Guggenheim Buy → Neutral
Jul-13-23 Initiated CapitalOne Overweight
Apr-03-23 Initiated Guggenheim Buy
Feb-06-23 Initiated Cantor Fitzgerald Overweight
Oct-31-22 Initiated BTIG Research Buy
Sep-13-22 Initiated Chardan Capital Markets Buy
Sep-11-19 Initiated Ladenburg Thalmann Buy
May-16-19 Initiated Oppenheimer Outperform
Apr-22-19 Initiated Ascendiant Capital Markets Buy
View All

Outlook Therapeutics Inc Stock (OTLK) Latest News

pulisher
Aug 20, 2025

Certain Warrants of Outlook Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 21-AUG-2025. - MarketScreener

Aug 20, 2025
pulisher
Aug 20, 2025

Will Outlook Therapeutics (OTLK) Stocks Rise? - StocksToTrade

Aug 20, 2025
pulisher
Aug 20, 2025

Outlook Therapeutics Reports Q3 Revenue - AOL.com

Aug 20, 2025
pulisher
Aug 20, 2025

Outlook Therapeutics Inc. Recovery Likely Here’s What Data ShowsJuly 2025 Summary & High Win Rate Trade Alerts - classian.co.kr

Aug 20, 2025
pulisher
Aug 19, 2025

Analysts’ Top Healthcare Picks: Outlook Therapeutics (OTLK), Pfizer (PFE) - The Globe and Mail

Aug 19, 2025
pulisher
Aug 18, 2025

Can Outlook Therapeutics Inc. Escape Recent Bear ChannelJuly 2025 Levels & Target Return Focused Stock Picks - 선데이타임즈

Aug 18, 2025
pulisher
Aug 18, 2025

Can Outlook Therapeutics Inc. Overcome Bearish SentimentEarnings Overview Summary & Low Drawdown Trading Techniques - newsyoung.net

Aug 18, 2025
pulisher
Aug 18, 2025

Outlook Therapeutics (OTLK.O) Surges 17.7%—What’s Fueling the Intraday Spike? - AInvest

Aug 18, 2025
pulisher
Aug 18, 2025

Outlook Therapeutics Inc. (OTLK) Soars 11.97% on FDA Decision Anticipation - AInvest

Aug 18, 2025
pulisher
Aug 18, 2025

Outlook Therapeutics Posts Q3 2025 Loss Amid High Operating Costs—Market Impact and Earnings Backtest Insights - AInvest

Aug 18, 2025
pulisher
Aug 17, 2025

Navigating Trade Turbulence: Outlook Therapeutics Faces Challenges from Global Trade Policies. - AInvest

Aug 17, 2025
pulisher
Aug 17, 2025

Chardan Capital Maintains Neutral Rating for Outlook Therapeutics with $3.00 Price Target - AInvest

Aug 17, 2025
pulisher
Aug 17, 2025

Outlook Therapeutics Reports Q3 2025 Earnings and Milestones - MSN

Aug 17, 2025
pulisher
Aug 17, 2025

Outlook Therapeutics Posts Another Loss in Q3 2025 Earnings — Market Impact Remains Mixed - AInvest

Aug 17, 2025
pulisher
Aug 17, 2025

Navigating Trade Turbulence: Outlook Therapeutics’ Struggle with Global Trade Policies - The Globe and Mail

Aug 17, 2025
pulisher
Aug 16, 2025

What makes Outlook Therapeutics Inc. stock attractive today2025 Major Catalysts & AI Enhanced Trading Signals - sundaytimes.kr

Aug 16, 2025
pulisher
Aug 16, 2025

Outlook Therapeutics Inc. Sees Relief Buying After Extended DropJuly 2025 Retail & Free Fast Entry Momentum Trade Alerts - metal.it

Aug 16, 2025
pulisher
Aug 16, 2025

Published on: 2025-08-16 19:04:04 - metal.it

Aug 16, 2025
pulisher
Aug 15, 2025

Outlook Therapeutics: Pivoting from R&D to Commercialization with LYTENAVA™ in Europe and FDA Approval on Horizon - AInvest

Aug 15, 2025
pulisher
Aug 15, 2025

Outlook Therapeutics (OTLK) Maintains Rating by Chardan Capital - GuruFocus

Aug 15, 2025
pulisher
Aug 15, 2025

Chardan Capital raises Outlook Therapeutics' PT to $3, maintains Neutral rating. - AInvest

Aug 15, 2025
pulisher
Aug 15, 2025

Outlook Therapeutics shares rise 4.12% premarket after reporting financial results for the third quarter. - AInvest

Aug 15, 2025
pulisher
Aug 14, 2025

Outlook Therapeutics Posts Q3 Revenue of $1.5mln, Meeting Estimates, and First-Ever Commercial Sales in Europe. - AInvest

Aug 14, 2025
pulisher
Aug 14, 2025

Outlook Therapeutics Inc Reports Q3 2025 Earnings: EPS of -$0.55 - GuruFocus

Aug 14, 2025
pulisher
Aug 14, 2025

Outlook Therapeutics Q3 FY2025 Financial Results and Corporate Update - TradingView

Aug 14, 2025
pulisher
Aug 14, 2025

Outlook Therapeutics reports Q3 adjusted EPS (44c) vs. (83c) last year - TipRanks

Aug 14, 2025
pulisher
Aug 14, 2025

Outlook Therapeutics at a Strategic Inflection Point: Regulatory and Commercial Catalysts for Value Creation in the $4B+ Anti-VEGF Market - AInvest

Aug 14, 2025
pulisher
Aug 14, 2025

Outlook Therapeutics reports Q3 net loss of $20.2mln, $1.5mln revenue. - AInvest

Aug 14, 2025
pulisher
Aug 14, 2025

Outlook Therapeutics Reports Financial Results for Third Quarter Fiscal Year 2025 and Provides Corporate Update - GlobeNewswire

Aug 14, 2025
pulisher
Aug 14, 2025

Outlook's Eye Drug LYTENAVA Launches in Europe as Critical FDA Decision Approaches - Stock Titan

Aug 14, 2025
pulisher
Aug 14, 2025

Will Outlook Therapeutics Inc. Hold Gains Into CloseEntry Point & Community Verified Watchlist Alerts - kangso.co.kr

Aug 14, 2025
pulisher
Aug 13, 2025

Reversal Traders Monitor Outlook Therapeutics Inc. for EntryChart Breakout Buy Signal Detection Confirmed - 선데이타임즈

Aug 13, 2025
pulisher
Aug 11, 2025

Outlook Therapeutics, Inc. shares rise 1.94% after-hours due to positive market sentiment. - AInvest

Aug 11, 2025
pulisher
Aug 11, 2025

SHAREHOLDER ALERT: Levi & Korsinsky Reminds Outlook Therapeutics, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of January 2, 2024OTLK - ACCESS Newswire

Aug 11, 2025
pulisher
Aug 08, 2025

Outlook Therapeutics Inc expected to post a loss of 39 cents a shareEarnings Preview - TradingView

Aug 08, 2025
pulisher
Aug 04, 2025

Published on: 2025-08-04 15:25:16 - metal.it

Aug 04, 2025
pulisher
Aug 04, 2025

What are analysts’ price targets for Outlook Therapeutics Inc. in the next 12 monthsUnlock high-yield investment opportunities - Jammu Links News

Aug 04, 2025
pulisher
Aug 04, 2025

What institutional investors are buying Outlook Therapeutics Inc. stockTriple-digit profit margins - Jammu Links News

Aug 04, 2025
pulisher
Aug 03, 2025

What are the latest earnings results for Outlook Therapeutics Inc.Game-changing capital returns - Jammu Links News

Aug 03, 2025
pulisher
Aug 03, 2025

What is the dividend policy of Outlook Therapeutics Inc. stockFree Capital Allocation Plans - Jammu Links News

Aug 03, 2025
pulisher
Aug 03, 2025

How volatile is Outlook Therapeutics Inc. stock compared to the marketExceptional portfolio growth - Jammu Links News

Aug 03, 2025
pulisher
Aug 03, 2025

When is Outlook Therapeutics Inc. stock expected to show significant growthExplosive portfolio gains - Jammu Links News

Aug 03, 2025
pulisher
Aug 03, 2025

Is Outlook Therapeutics Inc. a good long term investmentUnrivaled growth potential - Jammu Links News

Aug 03, 2025
pulisher
Aug 03, 2025

How strong is Outlook Therapeutics Inc. company’s balance sheetCapitalize on fast-growing stocks today - Jammu Links News

Aug 03, 2025
pulisher
Aug 03, 2025

What is the risk reward ratio of investing in Outlook Therapeutics Inc. stockFree Stock Chart Pattern Guide - Jammu Links News

Aug 03, 2025
pulisher
Aug 03, 2025

What makes Outlook Therapeutics Inc. stock price move sharplyInvest confidently with expert support - Jammu Links News

Aug 03, 2025
pulisher
Aug 03, 2025

What catalysts could drive Outlook Therapeutics Inc. stock higher in 2025Achieve breakthrough performance in the market - Jammu Links News

Aug 03, 2025
pulisher
Aug 03, 2025

Should I hold or sell Outlook Therapeutics Inc. stock in 2025Capitalize on emerging market sectors - Jammu Links News

Aug 03, 2025
pulisher
Aug 02, 2025

How does Outlook Therapeutics Inc. generate profit in a changing economyAchieve triple-digit returns with smart investing - Jammu Links News

Aug 02, 2025
pulisher
Aug 01, 2025

What is Outlook Therapeutics Inc. company’s growth strategyPre Market Recommendation With Low Risk - Jammu Links News

Aug 01, 2025
pulisher
Jul 31, 2025

Outlook Therapeutics, Inc. shares rise 1.95% premarket after Eli Lilly's Mounjaro shows heart benefits in a head-to-head study. - AInvest

Jul 31, 2025

Outlook Therapeutics Inc Stock (OTLK) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
$24.65
price up icon 0.94%
$85.04
price down icon 1.72%
$26.20
price up icon 0.73%
$110.88
price up icon 0.10%
$131.88
price down icon 0.54%
biotechnology ONC
$313.67
price down icon 0.10%
Cap:     |  Volume (24h):